Clinical Trial

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2023-02-21; most recent amendment 2026-05-27.
Status change: Recruiting → Active, Not Recruiting 2025-09-26
Status change: Not Yet Recruiting → Recruiting 2023-08-16
Trial Details
NCT Number NCT05743244
Lead Sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators: Pfizer
Conditions Diabetes Mellitus, Type 1
Enrollment 78 participants
Start Date 2023-10-19
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-29